65,437 trials
Cataract
Primary: Visual Acuity — 0.54; 0.06; 0.03; 0.04 logMAR
Healthy Volunteers
Primary: Cmax - Maximum Observed Plasma Concentration — 14.2; 13.6 ng/mL
Major Depressive Disorder
Primary: Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS) at 8 Weeks. — -12.8; -13.4; -10.1 Units on a scale
Healthy
Primary: Cmax - Maximum Observed Plasma Concentration — 47.4; 48.4 ng/mL
Alcoholism
Primary: The Weekly Mean Number of Standard Drinks Consumed Per Day at Baseline and Treatment Phase — -6.7 Standard Drinks — p=<0.0003
Influenza
Primary: Percentage of Subjects With Seroprotection, in Healthy Adults 18 to 64 Years of Age — 93; 96; 91; 99 Percentages of participants
Allergic Rhinitis
Primary: Fold Change From Baseline at Hour 8 in Interleukin 5 (IL-5) Concentration — 26.94; 6.70; 1.86 Fold Change — p=0.002
Carotid Artery Disease
Primary: Major Adverse Cardiac and Cerebrovascular Events (MACCE) Within 30 Days of the Procedure. — 0; 6; 0; 0 participants — p=<0.05
Arthritis, Rheumatoid
Primary: Disease Activity Score Using 28-joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4ESR) by Treatment Period. — 3.26; 3.13 units on scale
Cerebral Palsy · Child, Preschool
Primary: Pediatric Evaluation of Disability Inventory — 14.6; 6.4; 8.0; 7.9 Units on scale — p=0.02
Psoriasis
Primary: Physician Global Assessment of Psoriasis (PGA) Score - Mean Value Over 54 Weeks — 1.98; 2.51 units on scale — p=<0.001
Human · Papillomavirus Infections
Primary: Number of Participants Reporting Serious Adverse Experiences (SAEs) Through Month 18 — 6; 0 participants
Hereditary Angioedema (HAE)
Primary: Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose — 2.2; 2.0; 1.4; 1.6 units on a scale — p=0.010
Hereditary Angioedema
Primary: Frequency of All HAE Attacks — 3.00; 0.21 attacks per month
Hypertension · Pure Autonomic Failure
Primary: Change in Systolic Blood Pressure — 43; 21 mm Hg